ALPHAMAB ONCOLO.DL-000002 (F:3NK) — Stock Price
ALPHAMAB ONCOLO.DL-000002 (F:3NK) is currently trading at €0.90 EUR, up 1.13% today. Over the past 52 weeks, shares have ranged between €0.70 and €1.68. This page tracks ALPHAMAB ONCOLO.DL-000002's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see ALPHAMAB ONCOLO.DL-000002 (3NK) cash flow conversion.
ALPHAMAB ONCOLO.DL-000002 (3NK) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ALPHAMAB ONCOLO.DL-000002's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
ALPHAMAB ONCOLO.DL-000002 Income Statement — Revenue, Profit & Earnings by Year
ALPHAMAB ONCOLO.DL-000002's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €566.24 Million | €640.08 Million | €218.77 Million | €166.84 Million | €146.02 Million |
| Cost of Revenue | €63.55 Million | €60.32 Million | €55.24 Million | €44.21 Million | €3.03 Million |
| Gross Profit | €502.69 Million | €579.77 Million | €163.54 Million | €122.64 Million | €142.99 Million |
| Research & Development | €572.16 Million | €404.15 Million | €407.52 Million | €468.24 Million | €481.36 Million |
| SG&A | €83.82 Million | €74.61 Million | €79.34 Million | €86.77 Million | €77.25 Million |
| Total Operating Expenses | €702.01 Million | €526.31 Million | €524.32 Million | €575.32 Million | €548.01 Million |
| Operating Income | €-135.77 Million | €113.78 Million | €-305.55 Million | €-408.48 Million | €-401.99 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €7.45 Million | €9.92 Million | €12.18 Million | €14.21 Million | €13.18 Million |
| Income Before Tax | €-113.94 Million | €166.34 Million | €-210.59 Million | €-325.72 Million | €-412.42 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-113.94 Million | €166.34 Million | €-210.59 Million | €-325.72 Million | €-412.42 Million |
ALPHAMAB ONCOLO.DL-000002 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ALPHAMAB ONCOLO.DL-000002's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €2.10 Billion | €2.24 Billion | €2.14 Billion | €2.12 Billion | €2.71 Billion |
| Total Current Assets | €1.59 Billion | €1.71 Billion | €1.56 Billion | €1.49 Billion | €2.12 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €1.09 Billion | €459.35 Million | €321.25 Million | €281.19 Million | €1.18 Billion |
| Net Receivables | €61.95 Million | €16.52 Million | €7.13 Million | €15.49 Million | €7.61 Million |
| Inventory | €107.88 Million | €81.81 Million | €78.75 Million | €64.64 Million | €57.91 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €386.17 Million | €409.87 Million | €465.00 Million | €559.86 Million | €834.80 Million |
| Total Current Liabilities | €280.85 Million | €254.04 Million | €266.84 Million | €384.91 Million | €637.26 Million |
| Long-term Debt | €85.22 Million | €129.98 Million | €175.00 Million | €150.00 Million | €153.83 Million |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €1.71 Billion | €1.83 Billion | €1.67 Billion | €1.56 Billion | €1.87 Billion |
| Retained Earnings | €-2.29 Billion | €-2.18 Billion | €-2.34 Billion | €-2.13 Billion | €-1.81 Billion |
ALPHAMAB ONCOLO.DL-000002 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ALPHAMAB ONCOLO.DL-000002 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-121.89 Million | €212.34 Million | €-202.84 Million | €-300.31 Million | €-320.60 Million |
| Capital Expenditures | €31.59 Million | €21.77 Million | €36.18 Million | €129.65 Million | €158.12 Million |
| Free Cash Flow | €-153.48 Million | €190.56 Million | €-239.02 Million | €-429.96 Million | €-478.72 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €18.48 Million | €2.53 Million | €15.38 Million | €13.29 Million | €8.17 Million |
| Depreciation | €64.68 Million | €77.03 Million | €69.12 Million | €55.19 Million | €41.10 Million |
| Change in Cash | €-849.05 Million | €20.45 Million | €-2.87 Million | €239.55 Million | €617.57 Million |
ALPHAMAB ONCOLO.DL-000002 Earnings History — EPS Actual vs. Analyst Estimates
Track ALPHAMAB ONCOLO.DL-000002's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 27, 2026 | — | — | — |
| Mar 25, 2026 | — | — | — |